On December 3, BMO Capital’s Evan Seigerman increased the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $372 from $335 ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with diet and exercise alone, others find that adding weight loss medications like ...

Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial. The company announced Monday that it has ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. The company faces significant patent expiries but aims to offset losses with ...

Please provide your email address to receive an email when new articles are posted on . The MariTide trial evaluated once-monthly maridebart cafraglutide, a dual bispecific GLP-1 receptor agonist and ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea. The drug demonstrated 20% average ...